GLP-1 and Endurance Event Fuelling

Endurance fuelling and GLP-1 receptor agonists work against each other, and the conflict is mechanical rather than theoretical. Getting carbohydrate into working muscle during a long event depends on the stomach emptying quickly. Slowing gastric emptying is how these drugs work. Prescribing information documents that the delay can reduce absorption of orally administered substances, and carbohydrate faces the same physical constraint as any tablet does. What nobody has done is study race fuelling in people taking these drugs. There is no trial, no protocol and no validated per-hour target for this population, so everything practical below is extrapolation from mechanism and should be treated that way.

The evidence here is thin, and that is the first thing to say

No trial has studied endurance-event carbohydrate fuelling in people taking GLP-1 receptor agonists. Not underpowered, not mixed, absent.

What is established is the mechanism on both sides. Prescribing information documents delayed gastric emptying and its effect on oral absorption. Sports nutrition has decades of work on carbohydrate delivery rates in normal physiology. Putting the two together is reasonable inference, and inference is what it remains until someone runs the study.

Anyone offering you a specific gram-per-hour target for racing on a GLP-1 is extrapolating too, whether or not they say so.

The core conflict

Beyond roughly 90 minutes of hard work, performance depends on delivering carbohydrate from outside faster than muscle glycogen depletes. That delivery is rate-limited in two places: gastric emptying first, then intestinal transport.

A GLP-1 slows the first step directly. So an intake that worked reliably before you started the drug can now arrive later than expected, arrive incompletely, or sit in the stomach and cause distress at race intensity. Nausea at threshold pace with a stomach that will not empty is a specific and unpleasant failure mode.

The effect is largest after the first dose and after each dose escalation, then diminishes with continued exposure at a stable dose. Someone twelve months into maintenance is in a different position from someone three weeks into a titration step.

Standard per-hour targets are a hypothesis, not a plan

The familiar carbohydrate-per-hour figures come from research in athletes with normal gastric emptying. They are averages that already vary considerably between individuals before you add a drug that slows the rate-limiting step.

Treating your usual number as a starting hypothesis to test in training, rather than a plan to execute on race day, is the position the evidence supports. The number that works for you on this drug may be lower, and it may need to come in a different form.

Liquid, gel and solid

In normal physiology, liquids empty from the stomach faster than gels, which empty faster than solids. That ordering is why most people experimenting with fuelling on this drug class try moving toward more dilute liquid carbohydrate first.

Whether the ordering holds under GLP-1-delayed emptying has not been measured. It is a sensible first thing to test because it costs nothing and the underlying physiology is well described.

Test it in training at race intensity, not at easy pace. Gastric tolerance at conversational effort tells you very little about tolerance at race effort, and that gap is where race-day fuelling plans usually fail.

Carbohydrate loading in an energy deficit

Loading glycogen in the days before an event means eating a large amount of carbohydrate, which is difficult with suppressed appetite and reduced gastric capacity. It also runs directly against the energy deficit that the drug is there to produce.

There is no protocol validated for this population, and the tension between losing weight and preparing for an endurance event is real rather than something to be optimised away. If both matter to you, that ordering question, which one takes priority in a given block, is worth raising with your prescriber and with whoever coaches you.

Chronic energy deficit also means starting glycogen stores are less likely to be topped up in the first place, so the event begins from a lower reserve regardless of what you manage in the final 48 hours.

Hydration, heat and the kidney warning

Sweat losses during a long event continue at their normal rate whatever your appetite is doing. On top of that, reduced food intake means less water arriving with food, and early satiety limits how much can be drunk comfortably.

FDA labelling for this class warns about serious kidney injury following dehydration, with most reported cases following nausea, vomiting or diarrhoea. A long event in heat is a setting that combines high fluid loss, limited intake and a real chance of GI symptoms. That combination deserves respect rather than optimism.

Resting heart rate also runs a mean of 1 to 4 bpm higher on semaglutide, which matters if you pace by heart rate. Your zones may not mean quite what they used to, and our page on heart rate covers that.

Timing around dose escalation

The gastric-emptying effect is at its largest after each dose increase. Escalating in the weeks before a target event puts an untested variable into the most important session of your year.

Titration schedules are set by prescribers for clinical reasons, and an event date is one input among several. It is a reasonable thing to raise in advance rather than a decision to make yourself, and raising it early gives more room to accommodate.

Skipping or shifting a dose around a race is likewise a prescriber question. Do not self-adjust, and do not try anything new on race day that you have not tested in training.

Fitness itself

One more thing worth knowing before an event. In randomised data, cardiorespiratory fitness relative to fat-free mass improved around 10% in exercise and combined arms, and did not improve significantly with GLP-1 treatment alone.

Being lighter helps in some events and does not automatically make you fitter. The training is what does that, which is the same conclusion the running page reaches from a different direction.

Not medical advice

This page reports what prescribing information documents and states plainly where no evidence exists. It is general educational information, not advice about competing, fuelling or dosing. Whether to compete on a GLP-1 at all, and how to handle doses around an event, are conversations for your prescriber.

A first-person account, for context

Everything above is drawn from trial data and prescribing information. What that evidence cannot give you is what a GLP-1 block actually feels like week to week in someone training seriously.

Thomas Prommer, a competitive endurance athlete, has written up fuelling long races on a GLP-1, including what he could and could not stomach. Read it as one person's experience rather than as evidence. It is n=1, it is uncontrolled, and it describes an athlete population the trials on this page did not study. It is useful for exactly that reason and for no other.

The evidence, one row per claim

Sources

1. MOUNJARO US Prescribing Information, Eli Lilly
2. MOUNJARO US Prescribing Information, FDA
3. Physical Fitness with Exercise and GLP-1 RA Treatment (Sports Medicine)
4. OZEMPIC US Prescribing Information, FDA

Keep reading

• GLP-1 and Running: Endurance Training, Pace and FuellingBody mass falls, which helps. Glycogen availability falls and resting heart rate rises, which hurts. Aerobic f
• GLP-1 and Hydration: Why Fluid Intake Drops and Why It MattersA soft wellness topic with a hard regulatory warning behind it: dehydration following GI symptoms is the docum
• GLP-1 and GI Side Effects: Nausea, Constipation and RefluxGI effects are the dominant labelled adverse reactions, inseparable from how the drug works, and concentrated
• GLP-1 and Fasted TrainingAlmost everyone on this drug trains closer to fasted by default. The question that matters is whether total da
• GLP-1 and Heart Rate: The Resting Increase and What SELECT ShowedThe heart-rate rise is real, labelled and small. The outcome trial found a 20% reduction in major cardiovascul